Nuformix plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NFX.L research report →
Companywww.nuformix.com
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
- CEO
- Daniel John Gooding
- IPO
- 2015
- Employees
- 3
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $3.42M
- P/E
- -5.05
- P/S
- 0.00
- P/B
- 4.37
- EV/EBITDA
- -5.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -83.53%
- ROIC
- -85.04%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-652,586 · 82.08%
- EPS
- $0.00 · 100.00%
- Op Income
- $-660,569
- FCF YoY
- -85.19%
Performance & Tape
- 52W High
- $0.56
- 52W Low
- $0.07
- 50D MA
- $0.18
- 200D MA
- $0.22
- Beta
- 1.50
- Avg Volume
- 36.72M
Get TickerSpark's AI analysis on NFX.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NFX.L Coverage
We haven't published any research on NFX.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NFX.L Report →